Sarah Goldberg, MD, MPH, Yale School of Medicine

Panelists provide first impressions on recent clinical trials in the treatment of small cell lung cancer and comment on the safety and efficacy of study treatments.

Key opinion leaders provide insights on chemotherapy and radiotherapy in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC).

Experts in thoracic oncology discuss the role of single-agent immunotherapy as neoadjuvant therapy and comment on the viability of MPR [major pathologic response] as a surrogate endpoint for non–small cell lung cancer (NSCLC).

Key opinion leaders discuss recent trial data on the clinical efficacy of immunotherapy for the treatment of non–small cell lung cancer (NSCLC).

Panelists provide insight into emerging clinical trial data on antibody-drug conjugates (ADCs) presented at the IASLC 2020 World Conference on Lung Cancer (WCLC).

Experts in thoracic oncology review data presented at the IASLC 2020 World Conference on Lung Cancer (WCLC) and discuss safety and efficacy of targeted agents for patients with KRAS- or EGFR-mutated non–small cell lung cancer (NSCLC).